Osteoporosis International

, Volume 25, Issue 3, pp 953–964 | Cite as

Vertebral fracture assessment (VFA) by lateral DXA scanning may be cost-effective when used as part of fracture liaison services or primary care screening

  • E. M. Clark
  • L. Carter
  • V. C. Gould
  • L. Morrison
  • J. H. Tobias
Original Article

Abstract

Summary

We identified that use of VFA may be cost-effective in either selected women from primary care or women attending after a low trauma fracture.

Introduction

Lateral DXA scanning of the spine for vertebral fracture assessment (VFA) is used for research, but its wider role is unclear. We aimed to establish whether VFA is cost-effective in women based on two different scenarios: following a low-trauma fracture, and after screening of high-risk women identified in primary care.

Methods

The fracture cohort (FC) consisted of 377 women and the primary care cohort (PCC) of 251. Vertebral fractures were identified on VFA images by quantitative morphometry (QM). Outcome was cost-effectiveness of VFA, based on predicted change in clinical management defined as the identification of a vertebral fracture in a patient who otherwise falls below the threshold for treatment. FRAX treatment thresholds assessed were (1) 20/3 % thresholds and (2) National Osteoporosis Guidelines Group (NOGG) thresholds.

Results

As a result, 9.8 % from FC and 13.9 % from PCC were identified with vertebral fractures. Management was changed in 21 to 22/377 (5.6–5.8 %) in FC and 12 to 26/251 (4.8–10.4 %) from PCC depending on which thresholds were used. Sensitivity analyses identified medication adherence as the assumption which most influenced the model. The best-estimate cost-per-QALY for use of VFA in FC was £3,243 for 20/3 threshold and £2,130 for NOGG; for PCC, this was £7,831 for 20/3 and was cost-saving for NOGG. Further analyses to adjust for potential false-positive vertebral fracture identification with QM showed VFA was no longer cost-effective.

Conclusion

VFA appears to be cost-effective in routine clinical practise, particularly when relatively inaccurate methods of identification of vertebral fractures are used such as QM.

Keywords

COSHIBA Cost-effectiveness Fracture liaison Vertebral fracture VFA 

References

  1. 1.
    Melton LJ III, Atkinson EJ, Cooper C, O’Fallen WM, Riggs BL (1999) Vertebral fractures predict subsequent fractures. Osteoporos Int 10:214–221PubMedCrossRefGoogle Scholar
  2. 2.
    WHO Technical Support Series (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: Report of a WHO Study group. 843. WHO, GenevaGoogle Scholar
  3. 3.
    Kanis JA, Oden A, Johansson H, Borgstrom F, Strom O, McCloskey E (2009) FRAX and its applications to clinical practise. Bone 44:734–743PubMedCrossRefGoogle Scholar
  4. 4.
    Dawson-Hughes B (2008) Commentary: a revised clinician’s guide to the prevention and treatment of osteoporosis. J Clin Endocrinol Metab 93(7):2463–2465PubMedCrossRefGoogle Scholar
  5. 5.
    Compston J, Cooper A, Cooper C, Francis R, Kanis JA, Marsh D, McCloskey EV, Reid DM, Selby P, Wilkins M, on behalf of the National Osteoporosis Guideline Group (NOGG) (2008) Osteoporosis: Clinical guideline for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years on the UK. University of Sheffield PressGoogle Scholar
  6. 6.
    Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC et al (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348:1535–1541PubMedCrossRefGoogle Scholar
  7. 7.
    Cooper C, Atkinson EJ, O’Fallen WM, Melton LJ III (1992) Incidence of clinically diagnosed vertebral fractures: a population-based study in Rochester, Minnesota. J Bone Miner Res 7:221–227PubMedCrossRefGoogle Scholar
  8. 8.
    Clark EM, Gould VC, Morrison L, Ades AE, Dieppe P, Tobias JH (2012) Randomised controlled trial of a primary care-based screening programme to identify older women with prevalent osteoporotic vertebral fractures. J Bone Miner Res 27(3):664–671PubMedCentralPubMedCrossRefGoogle Scholar
  9. 9.
    Watson SJ, Jones AL, Oatway WB, Hughes JS (2005) Ionising radiation exposure of the UK population. 2005 Review HPA-RPD-001Google Scholar
  10. 10.
    Njeh CF, Fuerst T, Hans D, Blake GM, Genant HK (1999) Radiation exposure in bone mineral density assessment. Appl Radiat Isot 50(1):215–236PubMedCrossRefGoogle Scholar
  11. 11.
    Schousboe JT, Vokes T, Broy SB, Ferrar L, McKiernan F, Roux C, Binkley N (2008) VFA: the 2007 ISCD official positions. J Clin Densitom 11(1):92–108PubMedCrossRefGoogle Scholar
  12. 12.
    Genant HK, Wu CY, van Kuijk C, Nevitt MC (1993) VFA using a SQ technique. J Bone Miner Res 8(9):1137–1148PubMedCrossRefGoogle Scholar
  13. 13.
    Ferrar L, Jiang G, Schousboe JT, DeBold CR, Eastell R (2008) Algorithm-based qualitative and semiquantitative identification of prevalent vertebral fracture: agreement between different readers, imaging modalities, and diagnostic approaches. J Bone Miner Res 23(3):417–424PubMedCrossRefGoogle Scholar
  14. 14.
    Middleton ET, Steel SA (2008) Routine versus targeted VFA for the detection of vertebral fractures. Osteoporos Int 19:1167–1173PubMedCrossRefGoogle Scholar
  15. 15.
    van Brussel MS, Lems WF (2009) Clinical relevance of diagnosing vertebral fractures by VFA. Curr Osteoporos Rep 7:103–106PubMedCrossRefGoogle Scholar
  16. 16.
    Vokes TJ, Gillen DL (2010) Using clinical risk factors and BMD to determine who among patients undergoing bone densitometry should have VFA. Osteoporos Int 21:2083–2091PubMedCentralPubMedCrossRefGoogle Scholar
  17. 17.
    Gallacher SJ, Gallagher AP, McQuillian C, Mitchell PJ, Dixon T (2007) The prevalence of vertebral fracture amongst patients presenting with non-vertebral fractures. Osteoporos Int 18:185–192PubMedCentralPubMedCrossRefGoogle Scholar
  18. 18.
    Morrison LS, Tobias JH (2005) Effect of a case-finding strategy for osteoporosis on bisphosphonate prescribing in primary care. Osteoporos Int 16:71–77PubMedCrossRefGoogle Scholar
  19. 19.
    Clark EM, Gould V, Morrison L, Masud T, Tobias JH (2011) Determinants of fracture risk in a UK-population-based cohort of older women: a cross-sectional analysis of the Cohort for Skeletal Health in Bristol and Avon (COSHIBA). Age Ageing 41(1):46–52PubMedCrossRefGoogle Scholar
  20. 20.
    McLellan AR, Wolowacz SE, Zimovetz A, Beard SM, Lock S, McCrink L, Adekunle F, Roberts D (2011) FLS for the evaluation and management of patients with osteoporotic fracture: a cost-effectiveness evaluation based on data collected over 8 years of service provision. Osteoporos Int 22:2083–2098PubMedCrossRefGoogle Scholar
  21. 21.
    Li L, Roddam A, Gitlin M, Taylor A, Shepherd S, Shearer A, Jick S (2012) Persistence with osteoporosis medications among postmenopausal women in the UK GPRD. Menopause. J North Am Menopause Soc 19(1):33–40CrossRefGoogle Scholar
  22. 22.
    Office for National Statistics (2012) Death Registration Summary Tables, England and Wales, 2011. UK Statistics Authority. Table 1. CrownGoogle Scholar
  23. 23.
    Laster AJ, Lewiecki EM (2007) VFA by DXA: insurance coverage issues in the US. A white paper of the ISCD. J Clin Densitom 10(3):227–238PubMedCrossRefGoogle Scholar
  24. 24.
    British National Formulary (2012) BMJ Group and the Royal Pharmaceutical Society of Great BritainGoogle Scholar
  25. 25.
    Stevenson MD, Davis SE, Kanis JA (2006) The hospitalisation costs and out-patient costs of fragility fractures. Womens Health Med 3(4):149–151CrossRefGoogle Scholar
  26. 26.
    National Institute for Health and Clinical Excellence (2011) Hip fracture Costing Report: Implementing NICE guidance CG124Google Scholar
  27. 27.
    Hab B, Lungershausen J, Hertel N, Poulsen Nautrup B, Kotowa W, Liedgens H (2009) Cost-effectiveness of strong opiods focussing on the long-term effects of opiod-related fractures: a model approach. Eur J Health Econ 10:309–321CrossRefGoogle Scholar
  28. 28.
    Sullivan PW, Ghushchyan V (2006) Mapping the EQ-5D index from the SF-12: US general population preferences in a nationally representative sample. Med Decis Mak 26(4):401–409CrossRefGoogle Scholar
  29. 29.
    Hiligsmann M, Ethgen O, Richy F, Reginster JY (2008) Utility values associated with osteoporosis: a systematic review of the literature. Calcif Tissue Int 82(4):288–292PubMedCrossRefGoogle Scholar
  30. 30.
    Claxton K, Lindsay AB, Buxton MJ, Culyer AJ, McCabe C, Walker S, Sculpher MJ (2008) Value based pricing for NHS drugs: an opportunity not to be missed? BMJ 336:251–254PubMedCrossRefGoogle Scholar
  31. 31.
    Schousboe JT, Ensrud KE, Nyman JA, Kane RL, Melton LJ III (2006) Cost-effectiveness of VFA to detect prevalent vertebral deformity and select postmenopausal women with a femoral neck T-score >−2.5 for alendronate therapy: a modelling study. J Clin Densitom 9(2):133–143PubMedCrossRefGoogle Scholar
  32. 32.
    Olenginski TP, Newman ED, Hummel JL, Hummer M (2006) Development and evaluation of a VFA programme using IVA and its integration with mobile DXA. J Clin Densitom 9(1):72–77PubMedCrossRefGoogle Scholar
  33. 33.
    Jiang G, Ferrar L, Barrington N, Eastell R (2007) Standardised quantitative morphometry: a modified approach for quantitative identification of prevalent vertebral deformities. Osteoporos Int 18(10):1411–1419PubMedCrossRefGoogle Scholar
  34. 34.
    Grigoryan M, Guermazi A, Roemer FW, Delmas PD, Genant HK (2012) Recognising and reporting osteoporotic vertebral fractures. Eur Spine J 12(Suppl 2):S104–S112Google Scholar
  35. 35.
    Gallagher AM, Rietbrock S, Olson M, van Staa TP (2008) Fracture outcomes related to persistence and compliance with oral bisphosphonates. J Bone Miner Res 23(10):1569–1575PubMedCrossRefGoogle Scholar
  36. 36.
    Kanis JA, Cooper C, Hiligsmann M, Rabenda V, Reginster JY, Rizzoli R (2011) Partial adherence: a new perspective on health economic assessment in osteoporosis. Osteoporos Int 22(10):1565–2573CrossRefGoogle Scholar
  37. 37.
    Schousboe JT, Davison ML, Dowd B et al (2011) Predictors of patients perceived need for medication to prevent fracture. Med Care 49(3):273–280PubMedCrossRefGoogle Scholar
  38. 38.
    Hiligsmann M, Boonen A, Rabenda V, Reginster JY (2012) The importance of integrating medication adherence into pharmacoeconomic analyses: the example of osteoporosis. Expert Rev Pharmacoeconomics Outcomes Res 12(2):159–166CrossRefGoogle Scholar
  39. 39.
    National Institute for Clinical Excellence (2008) Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women: Technology Appraisal Guidance 161 (amended)Google Scholar
  40. 40.
    Dolan P (1997) Modelling valuations for EuroQol health states. Med Care 35(11):1095–1108PubMedCrossRefGoogle Scholar
  41. 41.
    Bergland A, Thorsen H, Karesen R (2011) Effect of exercise on mobility, balance and health-related quality of life in osteoporotic women with a history of vertebral fracture: a randomised controlled trial. Osteoporos Int 22:1863–1871PubMedCrossRefGoogle Scholar
  42. 42.
    Fuerst T, Wu C, Genant HK, von Ingersleben G, Chen Y, Johnston C, Econs MJ, Binkley N, Vokes TJ, Crans G, Mitlak BH (2009) Evaluation of VFA by DXA in a multicentre setting. Osteoporos Int 20(7):1199–1205PubMedCrossRefGoogle Scholar
  43. 43.
    Buehring B, Krueger D, Checovich M, Gemar D, Vallarta-Ast N, Genant HK, Binkley N (2010) VFA: impact of instrument and reader. Osteoporos Int 21(3):487–494PubMedCrossRefGoogle Scholar
  44. 44.
    Black DM, Thompson DE, Bauer DC, Ensrud K, Musliner T, Hochberg MC, Nevitt MC, Suryawanshi S, Cummings SR (2000) Fracture risk reduction with alendronate in women with osteoporosis: the fracture intervention trial. J Clin Endocrinol Metab 85(11):4118–4124PubMedCrossRefGoogle Scholar

Copyright information

© International Osteoporosis Foundation and National Osteoporosis Foundation 2013

Authors and Affiliations

  • E. M. Clark
    • 1
    • 2
  • L. Carter
    • 2
  • V. C. Gould
    • 1
  • L. Morrison
    • 1
  • J. H. Tobias
    • 1
    • 2
  1. 1.Musculoskeletal Research Unit, Avon Orthopaedic Centre, Southmead HospitalUniversity of BristolBristolUK
  2. 2.North Bristol NHS TrustBristolUK

Personalised recommendations